Compare
Q32 Bio Inc. vs Agios Pharmaceuticals, Inc. vs Integrated Biopharma Inc vs Nektar Therapeutics
| Latest fiscal year | Q32 Bio Inc. QTTB | Agios Pharmaceuticals, Inc. AGIO | Integrated Biopharma Inc INBP | Nektar Therapeutics NKTR |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-06-30 | 2025-12-31 |
| Revenue | $53.74M | $54.03M | $54.35M | $55.23M |
| Revenue growth (YoY) | n/a | +48.0% | +8.0% | -43.9% |
| Gross margin | n/a | 88.3% (computed) | 10.2% | n/a |
| Operating margin | 31.5% | -873.9% | 3.7% | -253.7% |
| Net margin | 55.5% | -764.0% | 1.5% | -297.1% |
| Net income | $29.82M | -$412.78M | $808.0K | -$164.08M |
| EPS (Diluted) | $2.42 | -$7.12 | $0.03 | -$9.73 |
| Operating cash flow | -$33.54M | -$372.98M | $2.06M | -$208.51M |
| Free cash flow | -$33.54M | -$377.29M | $1.87M | -$208.68M |
| Cash & equivalents | $48.30M | $89.13M | $3.62M | $15.12M |
| Total assets | $61.78M | $1.30B | $24.90M | $280.41M |
| Total liabilities | $19.76M | $104.11M | $4.58M | $190.57M |
| Shareholders' equity | $42.01M | $1.19B | $20.32M | $89.83M |
| Return on year-end equity | 71.0% | -34.6% | 4.0% | -182.6% |
| Shares outstanding | 12.86M | 58.45M | 31.06M | 20.38M |
Revenue, most recent five fiscal years
| Fiscal year | Q32 Bio Inc. | Agios Pharmaceuticals, Inc. | Integrated Biopharma Inc | Nektar Therapeutics |
|---|---|---|---|---|
| Latest | $53.74M Ended 2025-12-31 | $54.03M Ended 2025-12-31 | $54.35M Ended 2025-06-30 | $55.23M Ended 2025-12-31 |
| 1 year earlier | $0 Ended 2024-12-31 | $36.50M Ended 2024-12-31 | $50.32M Ended 2024-06-30 | $98.43M Ended 2024-12-31 |
| 2 years earlier | -$6.65M Ended 2023-12-31 | $26.82M Ended 2023-12-31 | $50.67M Ended 2023-06-30 | $90.12M Ended 2023-12-31 |
| 3 years earlier | n/a | $14.24M Ended 2022-12-31 | $56.25M Ended 2022-06-30 | $92.06M Ended 2022-12-31 |
| 4 years earlier | n/a | $0 Ended 2021-12-31 | $63.56M Ended 2021-06-30 | $101.91M Ended 2021-12-31 |